首頁 › 急性髓系白血病 › 堪薩斯 › Overland Park
Overland Park, KS 的 急性髓系白血病 臨床試驗
11 項針對 急性髓系白血病 的研究正在 Overland Park（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
招募中2 期
- University of Kansas Cancer Center-Overland Park, Overland Park
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- University of Kansas Clinical Research Center, Fairway · 距離 3 英里
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
招募中2 期
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- University of Kansas Clinical Research Center, Fairway · 距離 3 英里
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
招募中2 期
- University of Kansas Clinical Research Center, Fairway · 距離 3 英里
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
招募中2 期
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- University of Kansas Clinical Research Center, Fairway · 距離 3 英里
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
招募中2 期
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- University of Kansas Clinical Research Center, Fairway · 距離 3 英里
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
招募中3 期
- US-Kansas City KS-KUMC, Fairway · 距離 3 英里
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
招募中1 期
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- University of Kansas Clinical Research Center, Fairway · 距離 3 英里
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
招募中1 期
- The University of Kansas Medical Center Research Institute, Fairway · 距離 3 英里
APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
招募中1 期
- University of Kansas, Fairway · 距離 3 英里
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
招募中2 期
- University of Kansas Cancer Center, Fairway · 距離 3 英里
Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02
招募中1 期
- University of Kansas Cancer Center, Fairway · 距離 3 英里
其他城市的 急性髓系白血病 試驗
- Houston, TX85 項研究
- New York City, NY51 項研究
- Boston, MA44 項研究
- Seattle, WA41 項研究
- Baldwin Park, CA40 項研究
- Columbus, OH35 項研究
- Philadelphia, PA34 項研究
- Durham, NC33 項研究
- Atlanta, GA31 項研究
- Tampa, FL29 項研究
- Chicago, IL26 項研究
- Portland, OR25 項研究
Overland Park 的其他研究
- 非小細胞肺癌16 項研究
- 肺癌11 項研究
- 乳癌10 項研究
- 心房顫動8 項研究
- 大腸直腸癌8 項研究
- 肥胖症7 項研究
- 胰臟癌7 項研究
- 前列腺癌7 項研究
- 黑色素瘤6 項研究
- 過重6 項研究
- 卵巢癌6 項研究
- 癌症（所有類型）5 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。